Adipotide Peptide: Prohibitin-Targeting Fat Vasculature Agent and Its Limits
Adipotide peptide guide covering prohibitin-targeted fat vasculature apoptosis, the obese-monkey study, the halted Phase 1 trial and serious renal toxicity limits.
Adipotide is one of the most misunderstood compounds in the fat-loss peptide world. It was a genuinely innovative academic idea, it produced dramatic results in obese monkeys, and it then failed to become a usable human drug. Vendors that sell it as a "fat-targeting peptide" almost always skip that last part.
The compound, also written as FTPP or prohibitin-targeting peptide, is a chimeric peptidomimetic with the sequence CKGGRAKDC-GG-D(KLAKLAK)2. It does not work like an appetite-based therapy. Instead of acting on hunger or metabolism the way GLP-1 medicines for weight loss do, it was designed to physically destroy the blood supply that feeds white fat.
This guide is educational and not medical advice. Adipotide is not an approved medicine, it is not a supplement, and it is not a validated human weight-loss protocol. Nothing here should be read as instructions for use.
Adipotide At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic pro-apoptotic peptidomimetic, CKGGRAKDC-GG-D(KLAKLAK)2, also called FTPP. |
| What does it target? | Prohibitin on the endothelium of white adipose tissue blood vessels. |
| Origin | Kolonin, Saha, Chan, Pasqualini and Arap; first described in Nature Medicine in 2004, named Adipotide in the 2011 primate study. |
| Best evidence | A 28-day study in obese rhesus monkeys (Science Translational Medicine, 2011) and earlier rodent work. |
| Human status | Research-only and unapproved; a first-in-human Phase 1 oncology trial was halted and development discontinued. |
| Main safety frame | Dose-dependent renal toxicity, the central reason it did not advance in humans. |
How Adipotide Was Designed To Work
Most fat-loss drugs act on signaling. Adipotide was built on a completely different premise: starve the fat tissue by killing its blood vessels.
White adipose tissue, like any living tissue, depends on a dedicated blood supply. Using a technique called in vivo phage display, the original 2004 Nature Medicine team isolated a short peptide motif, CKGGRAKDC, that selectively "homes" to the vasculature of white fat. They identified its molecular partner as prohibitin, a multifunctional membrane protein expressed on the luminal surface of endothelial cells in fat blood vessels. Later work described an annexin A2-prohibitin receptor system on that same vasculature.
The homing motif alone does nothing harmful. The destructive part is a second segment fused to it: D(KLAKLAK)2, a D-amino-acid pro-apoptotic peptide. Once the homing motif docks onto prohibitin and the molecule is internalized into the endothelial cell, the D(KLAKLAK)2 segment disrupts mitochondrial membranes, which triggers apoptosis, programmed cell death. The vessel cells die, the local blood supply regresses, and the fat that depended on it shrinks.
In short, adipotide is a targeted "address label" (the prohibitin-binding motif) attached to a "warhead" (the mitochondrial-disrupting peptide). That architecture is clever, but it also explains the safety problem discussed below: prohibitin and the warhead's effects are not perfectly confined to fat.
What The Animal Evidence Actually Showed
The headline data come from animals, and they were striking. In the 2011 Science Translational Medicine study, obese rhesus monkeys received adipotide by daily subcutaneous injection. In the fixed-dose efficacy arm at 0.43 mg/kg per day for 28 days, treated monkeys lost roughly 7 to 15 percent of body weight, and total body fat fell by about 39 percent versus about 15 percent in controls (Barnhart et al., topline figures from the study). Insulin resistance also improved. Earlier rodent work in the 2004 Nature Medicine paper had shown resorption of established white fat and normalization of metabolism.
Three honest caveats matter:
First, these are short studies in animals. A 28-day result in ten monkeys is a proof of concept, not evidence of safe, durable human weight loss.
Second, the effect size is partly the point of caution. A therapy that can strip 39 percent of body fat in four weeks by killing blood vessels is, by design, doing something aggressive to living tissue.
Third, even in these favorable animal studies the kidney signal was already visible. The researchers reported mild, dose-dependent, reversible renal changes. That foreshadowed the human problem.
The Human Story: A Halted Program
This is the part most marketing copy omits. Adipotide did reach humans, and the result was not a success.
A first-in-human Phase 1 trial (ClinicalTrials.gov NCT01262664), run at MD Anderson Cancer Center, evaluated a single 28-day cycle of "prohibitin targeting peptide 1" in men with metastatic, castration-resistant prostate cancer who were also obese. The dose-escalation design started low, around 0.03 mg/kg per day subcutaneously, aiming to find a maximum tolerated dose. The oncology framing was deliberate: it allowed testing in patients with advanced disease where the risk-benefit calculus differs from healthy weight loss.
The program did not advance to a viable obesity therapy. Reporting on the compound describes the human trial being stopped and clinical development being discontinued, with nephrotoxicity, kidney toxicity, as the central concern. There is no published, peer-reviewed evidence establishing a safe and effective human dose for weight loss. Anyone presenting adipotide as a proven human fat-loss agent is contradicting the actual regulatory and clinical record.
Safety: Why The Mechanism Cuts Both Ways
| Safety issue | Why it matters |
|---|---|
| Renal toxicity | The defining problem. Dose-dependent kidney effects appeared even in monkeys and are the main reason human development stopped. |
| Off-target prohibitin | Prohibitin is not unique to fat vessels; it is a widely expressed mitochondrial and membrane protein, so "selective" is relative. |
| Pro-apoptotic warhead | D(KLAKLAK)2 is designed to kill cells; any mistargeting carries real consequences. |
| No human safety database | Without completed trials, there is no established adverse-event profile, drug-interaction data or long-term safety record. |
| Unregulated sourcing | Material sold online is research-grade, not pharmaceutical-grade, with no guarantee of identity, purity or sterility. |
| Unknown human pharmacokinetics | Human half-life and clearance are not well characterized; animal dosing was once daily by injection. |
The deeper point is that adipotide's strength and its danger are the same property. A blood-vessel-ablating, apoptosis-inducing peptide is powerful precisely because it destroys tissue. When the target is not perfectly confined, that power becomes the liability.
How To Evaluate An Adipotide Claim
Because adipotide is research-only, the most useful skill is spotting misleading framing. Ask these questions:
First, does the source mention that the impressive numbers come from monkeys and rodents, not humans? If it quotes the 39 percent fat-loss figure without that context, it is being selective.
Second, does it acknowledge the halted Phase 1 trial and the discontinued program? Omitting that is a major red flag.
Third, does it name the renal toxicity? A discussion of adipotide that never mentions kidneys is incomplete.
Fourth, is it implying a human dose? There is no approved or validated human weight-loss dose. Any "protocol" is extrapolated from animal milligram-per-kilo figures, which is not the same thing.
Fifth, how does it compare adipotide to therapies that did succeed? Approved modern weight-loss drugs such as semaglutide and tirzepatide reached the market through completed human trials and ongoing safety monitoring. Adipotide did not. That difference is the entire story.
For broader context, see how adipotide differs from the rest of the peptides studied for weight loss, the basics of what peptides are, and why peptide half-life and clearance matter for any injected compound.
Adipotide Versus Appetite-Based Therapies
It is worth being explicit about the contrast. GLP-1-class drugs reduce body weight largely by reducing appetite and slowing gastric emptying, and they are reversible: stop the drug and the receptor signaling stops. Adipotide was designed to do something structural and harder to undo, destroy the fat tissue's blood supply. In theory that promised faster, "diet-independent" fat loss. In practice, the structural mechanism is exactly what made off-target toxicity so consequential, and it is the approach that failed to clear human safety review, while the appetite-based approach became the dominant, approved standard.
Bottom Line
Adipotide is a scientifically interesting compound with a clear cautionary arc. The prohibitin-targeting concept was original, the obese-monkey data were dramatic, and the underlying biology genuinely advanced understanding of fat vasculature.
But the practical verdict is unambiguous. Adipotide is research-only and unapproved. It has no validated human weight-loss dose, no completed pivotal trials, and a first-in-human program that was halted with nephrotoxicity as the central concern. The same mechanism that made it powerful in animals, killing blood vessels through targeted apoptosis, is what made it too risky to advance.
Treat any product or claim presenting adipotide as a safe, proven fat-loss peptide with deep skepticism. The honest summary is that it is a discontinued investigational agent, not a weight-loss solution.
References
Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science Translational Medicine, 2011.
Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys (PMC full text).
Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nature Medicine, 2004.
Kolonin MG, et al. Reversal of obesity by targeted ablation of adipose tissue (PubMed).
Salameh A, et al. Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue. JCI Insight, 2016.
Salameh A, et al. Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue (PMC full text).
ClinicalTrials.gov. A First-in-Man, Phase I Evaluation of a Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity (NCT01262664).